학술논문
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Document Type
Article
Author
Source
In: The Lancet Gastroenterology and Hepatology . (The Lancet Gastroenterology and Hepatology, November 2021, 6(11):889-902)
Subject
Language
English
ISSN
24681253